Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03529110
Title DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Daiichi Sankyo, Inc.
Indications

Her2-receptor positive breast cancer

Therapies

Trastuzumab deruxtecan

Ado-trastuzumab emtansine

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.